Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Active Filter(s):
Details:
The primary endpoint was the time to clinical improvement. The medication failed to improve the condition or prevent the death of severely-affected Covid-19 patients, compared to standard care.
Lead Product(s): Lopinavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
The company is collaborating with select health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19.
Lead Product(s): Lopinavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: European Health Authorities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 09, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
The ‘4-in-1’ combination contains an antiretroviral combination of Abacavir, as an alternative first-line regimen for infants and young children with HIV – in the form of granule-filled capsules.
Lead Product(s): Abacavir,Lamivudine,Lopinavir
Therapeutic Area: Infections and Infectious Diseases Product Name: ABC/3TC/LPV/r
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
The results of the randomized controlled, open-labelled, multicenter, non-inferiority study showed successful achievement of the primary endpoint, with a good proportion of patients on the ABT regimen with HIV RNA less than 50 copies/mL at 48 weeks.
Lead Product(s): Albuvirtide,Lopinavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Aikening
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
Details:
A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality (19% azithromycin vs. 19% usual care) There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.
Lead Product(s): Azithromycin,Lopinavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
The trial will begin testing, against a control arm, the HIV antiretroviral combination lopinavir/ritonavir with a loaded dose and the malaria drug hydroxychloroquine, which remains the standard of care for COVID-19 today in numerous African countries.
Lead Product(s): Lopinavir,Ritonavir,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Inserm-ANRS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
Interim data from the WHO-coordinated Solidarity Therapeutics Trial suggest that remdesivir, hydroxychloroquine, lopinavir / ritonavir, and interferon regimens in COVID patients have little or no impact on 28-day mortality or the in-hospital course of COVID-19.
Lead Product(s): Remdesivir,Lopinavir,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: World Health Organization
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
The trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm.
Lead Product(s): Lopinavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
Details:
Trial revealed that patients treated with triple drug combination (lopinavir–ritonavir and ribavirin) tested negative for COVID-19 five days earlier than those treated with lopinavir–ritonavir alone.
Lead Product(s): Lopinavir,Ritonavir,Ribavirin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2020
Details:
Lopinavir and ritonavir - are the protease inhibitors that are designed to block HIV viral replication and are now being repurposed to deal with coronavirus.
Lead Product(s): Lopinavir,Ritonavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2020
